牛巴貝西蟲免疫熒光玻片

babesia bovis IFA Substrate slide

廣州健侖生物科技有限公司

主要用途：用于檢測牛血清中的牛巴貝西蟲IgG/IgM抗體

產(chǎn)品規(guī)格：12 孔/張,10 張/盒

主要產(chǎn)品包括：包柔氏螺旋體菌、布魯氏菌、貝納特氏立克次體、土倫桿菌、鉤端螺旋體、新型立克次體、恙蟲病、立克次體、果氏巴貝西蟲、馬焦蟲、牛焦蟲、利什曼蟲、新包蟲、弓形蟲、貓流感病毒、貓冠狀病毒、貓皰疹病毒、犬瘟病毒、犬細(xì)小病毒等病原微生物的 IFA、MIF、ELISA試劑。

牛巴貝西蟲免疫熒光玻片

我司還提供其它進口或國產(chǎn)試劑盒：登革熱、瘧疾、西尼羅河、立克次體、無形體、蜱蟲、恙蟲、利什曼原蟲、RK39、漢坦病毒、深林腦炎、流感、A鏈球菌、合胞病毒、腮病毒、乙腦、寨卡、黃熱病、基孔肯雅熱、克錐蟲病、違禁品濫用、肺炎球菌、軍團菌、化妝品檢測、食品安全檢測等試劑盒以及日本生研細(xì)菌分型診斷血清、德國SiFin診斷血清、丹麥SSI診斷血清等產(chǎn)品。

歡迎咨詢

歡迎咨詢2042552662

二維碼掃一掃

【公司名稱】 廣州健侖生物科技有限公司
【】    楊永漢 
【】 
【騰訊 】 2042552662
【公司地址】 廣州清華科技園創(chuàng)新基地番禺石樓鎮(zhèn)創(chuàng)啟路63號二期2幢101-3室
【企業(yè)文化】

文章的通訊作者Benz指出，我們組織中大部分是由許多不同類型的上皮細(xì)胞和非上皮細(xì)胞組成，“這項抗原抗體性的基因組研究不僅挑戰(zhàn)了基于組織類型的現(xiàn)有癌癥分類系統(tǒng)，而且還提供了能用于進一步研究的大量新數(shù)據(jù)來源，以及能用于區(qū)分每種新描述癌癥類型的分子特征整體列表，”Benz說，“比如說膀胱癌能重新被分成幾種不同的癌癥類型，每一種都具有不同的臨床表征，這就有助于解釋對看似相同的癌癥類型進行相同的全身療法治療，為什么患者往往反應(yīng)截然不同”。
這一研究組發(fā)現(xiàn)在十個癌癥患者中至少有一個能通過這種新系統(tǒng)分類到不同的癌癥類型中，而且Benz認(rèn)為如果他們下一輪進行更多的樣品，和腫瘤類型的分析，將會有更多的腫瘤需要重新分類，他預(yù)計下一輪將進行超過20種不同腫瘤類型的分析。
“考慮到這種多平臺類型基因組分析的潛力，我們還只是分析了冰山的一角。未來可能還有多達(dá)30%或 50%的癌癥需要被重新歸類”。
在這項研究中，zui引人注目的發(fā)現(xiàn)就是膀胱癌和抗原抗體癌方面的成果，至少有三個不同亞型的膀胱癌需要重新分類：一種是無法與肺腺癌區(qū)分開來的亞型，一種是與起源自頭部，頸部和肺部的鱗狀上皮細(xì)胞癌很相似的亞型。
這項研究也指出和證實了抗原抗體癌類型中已知的差異，而且還揭示出了新的令人驚訝的發(fā)現(xiàn)——基底樣抗原抗體癌實際上是一類新癌癥類型。
基底樣抗原抗體癌(Basal-like breast cancers)通常稱為三陰性抗原抗體癌(triple-negative breast cancer)，是一種特別具有侵襲性，并致命的癌癥。“即使這些基底樣癌癥出現(xiàn)在抗原抗體中，但在分子水平上它們與卵巢癌和鱗狀上皮細(xì)胞起源的癌癥更為相似，”Yau說。

Benz, the article's author, notes that most of our tissue is made up of many different types of epithelial cells and non-epithelial cells. "This antigen-antibody genomic study not only challenged existing cancer classification systems based on tissue type but also Provides a host of new sources of data that can be used for further research, as well as a comprehensive list of molecular features that can be used to differentiate each newly described cancer type, "says Benz." For example, bladder cancer can be subdivided into several different cancer types, Each has a different clinical manifestation, which helps to explain why patients often respond differently to seemingly identical types of cancer for the same systemic therapy. "
The team found that at least one out of ten cancer patients could be classified into different cancer types by this new system, and that Benz believes that if they do more samples in the next round, and tumor types will be analyzed There are more tumors that need to be reclassified, and he expects the next round of analysis to be performed on more than 20 different tumor types.
"Given the potential of this multiplatform type of genomic analysis, we're still just analyzing the tip of the iceberg, and perhaps as many as 30 or 50% of cancers need to be reclassified in the future."
The most striking finding in this study is the result of bladder cancer and antigen-antibody cancers that require reclassification of at least three different subtypes of bladder cancer: one that is indistinguishable from lung adenocarcinoma One that is very similar to squamous cell carcinoma, which originates from the head, neck and lung.
This study also points to and confirms the known differences in antigen-antibody cancer types and reveals new and surprising findings that basal-like antigen-antibody cancer is actually a new class of cancer.
Basal-like breast cancers, commonly known as triple-negative breast cancers, are a particularly aggressive and deadly cancer. "Even though these basal-like cancers are present in antigen-antibodies, they are more like molecularly cancers of ovarian and squamous cell origin," Yau said.